APA (7th ed.) Citation

Feng, W., Chen, X., Guan, S., Ruan, H., Huang, Y., Zhang, H., . . . Zhang, L. (2022). Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics. Acta pharmacologica Sinica, 43(7), 1857-1864. https://doi.org/10.1038/s41401-021-00791-5

Chicago Style (17th ed.) Citation

Feng, Wei, et al. "Rational Application of Gefitinib in NSCLC Patients with Sensitive EGFR Mutations Based on Pharmacokinetics and Metabolomics." Acta Pharmacologica Sinica 43, no. 7 (2022): 1857-1864. https://doi.org/10.1038/s41401-021-00791-5.

MLA (9th ed.) Citation

Feng, Wei, et al. "Rational Application of Gefitinib in NSCLC Patients with Sensitive EGFR Mutations Based on Pharmacokinetics and Metabolomics." Acta Pharmacologica Sinica, vol. 43, no. 7, 2022, pp. 1857-1864, https://doi.org/10.1038/s41401-021-00791-5.